S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

ITCI Intra Cellular Therapies Inc

83.23

1.45 (1.77%)

08 Jan 2025 - Closed

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Intra Cellular Therapies Charts.

Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Intra Cellular Therapies Charts.

Intra Cellular Therapies Inc News

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Tuesday 7 January 2025 (2 days ago) • GlobeNewswire Inc.

Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting
Thursday 12 December 2024 (4 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 7 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Friday 6 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Thursday 5 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 3 December 2024 (1 month ago) • Edgar (US Regulatory)

Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
Tuesday 3 December 2024 (1 month ago) • GlobeNewswire Inc.

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
Wednesday 20 November 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Saturday 9 November 2024 (2 months ago) • Edgar (US Regulatory)

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
Friday 8 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 5 November 2024 (2 months ago) • Edgar (US Regulatory)

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia
Tuesday 5 November 2024 (2 months ago) • GlobeNewswire Inc.

More Intra Cellular Therapies Inc News Articles

Martin Marietta Materials

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions